Literature DB >> 19357236

Facilitated maturation of Ca2+ handling properties of human embryonic stem cell-derived cardiomyocytes by calsequestrin expression.

Jing Liu1, Deborah K Lieu, Chung Wah Siu, Ji-Dong Fu, Hung-Fat Tse, Ronald A Li.   

Abstract

Cardiomyocytes (CMs) are nonregenerative. Self-renewable pluripotent human embryonic stem cells (hESCs) can differentiate into CMs for cell-based therapies. We recently reported that Ca(2+) handling, crucial to excitation-contraction coupling of hESC-derived CMs (hESC-CMs), is functional but immature. Such immature properties as smaller cytosolic Ca(2+) transient amplitudes, slower kinetics, and reduced Ca(2+) content of sarcoplasmic reticulum (SR) can be attributed to the differential developmental expression profiles of specific Ca(2+) handling and regulatory proteins in hESC-CMs and their adult counterparts. In particular, calsequestrin (CSQ), the most abundant, high-capacity but low-affinity, Ca(2+)-binding protein in the SR that is anchored to the ryanodine receptor, is robustly expressed in adult CMs but completely absent in hESC-CMs. Here we hypothesized that gene transfer of CSQ in hESC-CMs suffices to induce functional improvement of SR. Transduction of hESC-CMs by the recombinant adenovirus Ad-CMV-CSQ-IRES-GFP (Ad-CSQ) significantly increased the transient amplitude, upstroke velocity, and transient decay compared with the control Ad-CMV-GFP (Ad-GFP) and Ad-CMV-CSQDelta-IRES-GFP (Ad-CSQDelta, which mediated the expression of a nonfunctional, truncated version of CSQ) groups. Ad-CSQ increased the SR Ca(2+) content but did not alter L-type Ca(2+) current. Pharmacologically, untransduced wild-type, Ad-GFP-, Ad-CSQDelta-, and Ad-CSQ-transduced hESC-CMs behaved similarly. Whereas ryanodine significantly reduced the Ca(2+) transient amplitude and slowed the upstroke, thapsigargin slowed the decay. Neither triadin nor junctin was affected. We conclude that CSQ expression in hESC-CMs facilitates Ca(2+) handling maturation. Our results shed insights into the suitability of hESC-CMs for therapies and as certain heart disease models for drug screening.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19357236      PMCID: PMC2711646          DOI: 10.1152/ajpcell.00060.2009

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  39 in total

Review 1.  Cardiac excitation-contraction coupling.

Authors:  Donald M Bers
Journal:  Nature       Date:  2002-01-10       Impact factor: 49.962

2.  Calsequestrin is an inhibitor of skeletal muscle ryanodine receptor calcium release channels.

Authors:  Nicole A Beard; Magdalena M Sakowska; Angela F Dulhunty; Derek R Laver
Journal:  Biophys J       Date:  2002-01       Impact factor: 4.033

3.  Differentiation of human embryonic stem cells to cardiomyocytes: role of coculture with visceral endoderm-like cells.

Authors:  Christine Mummery; Dorien Ward-van Oostwaard; Pieter Doevendans; Rene Spijker; Stieneke van den Brink; Rutger Hassink; Marcel van der Heyden; Tobias Opthof; Martin Pera; Aart Brutel de la Riviere; Robert Passier; Leon Tertoolen
Journal:  Circulation       Date:  2003-05-12       Impact factor: 29.690

Review 4.  T-tubule function in mammalian cardiac myocytes.

Authors:  Fabien Brette; Clive Orchard
Journal:  Circ Res       Date:  2003-06-13       Impact factor: 17.367

5.  Evidence for Ca(2+) activation and inactivation sites on the luminal side of the cardiac ryanodine receptor complex.

Authors:  L L Ching; A J Williams; R Sitsapesan
Journal:  Circ Res       Date:  2000-08-04       Impact factor: 17.367

6.  Modulation of focal and global Ca2+ release in calsequestrin-overexpressing mouse cardiomyocytes.

Authors:  W Wang; L Cleemann; L R Jones; M Morad
Journal:  J Physiol       Date:  2000-04-15       Impact factor: 5.182

7.  Absence of transverse tubules contributes to non-uniform Ca(2+) wavefronts in mouse and human embryonic stem cell-derived cardiomyocytes.

Authors:  Deborah K Lieu; Jing Liu; Chung-Wah Siu; Gregory P McNerney; Hung-Fat Tse; Amir Abu-Khalil; Thomas Huser; Ronald A Li
Journal:  Stem Cells Dev       Date:  2009-12       Impact factor: 3.272

Review 8.  Calsequestrin and the calcium release channel of skeletal and cardiac muscle.

Authors:  N A Beard; D R Laver; A F Dulhunty
Journal:  Prog Biophys Mol Biol       Date:  2004-05       Impact factor: 3.667

9.  Reduced synchrony of Ca2+ release with loss of T-tubules-a comparison to Ca2+ release in human failing cardiomyocytes.

Authors:  William E Louch; Virginie Bito; Frank R Heinzel; Regina Macianskiene; Johan Vanhaecke; Willem Flameng; Kanigula Mubagwa; Karin R Sipido
Journal:  Cardiovasc Res       Date:  2004-04-01       Impact factor: 10.787

10.  Calsequestrin determines the functional size and stability of cardiac intracellular calcium stores: Mechanism for hereditary arrhythmia.

Authors:  Dmitry Terentyev; Serge Viatchenko-Karpinski; Inna Györke; Pompeo Volpe; Simon C Williams; Sandor Györke
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-16       Impact factor: 11.205

View more
  56 in total

1.  Determination of the human cardiomyocyte mRNA and miRNA differentiation network by fine-scale profiling.

Authors:  Joshua E Babiarz; Morgane Ravon; Sriram Sridhar; Palanikumar Ravindran; Brad Swanson; Hans Bitter; Thomas Weiser; Eric Chiao; Ulrich Certa; Kyle L Kolaja
Journal:  Stem Cells Dev       Date:  2012-01-04       Impact factor: 3.272

Review 2.  Maturing human pluripotent stem cell-derived cardiomyocytes in human engineered cardiac tissues.

Authors:  Nicole T Feric; Milica Radisic
Journal:  Adv Drug Deliv Rev       Date:  2015-05-05       Impact factor: 15.470

3.  Icariin induces mouse embryonic stem cell differentiation into beating functional cardiomyocytes.

Authors:  Xiaodong Sun; Xiuwei Sun; Xiudong Jin; Xiaoli Zhang; Chunling Liu; Lei Lei; Lianhong Jin; Huiwen Liu
Journal:  Mol Cell Biochem       Date:  2010-12-23       Impact factor: 3.396

4.  Anisotropic microfibrous scaffolds enhance the organization and function of cardiomyocytes derived from induced pluripotent stem cells.

Authors:  Maureen Wanjare; Luqia Hou; Karina H Nakayama; Joseph J Kim; Nicholas P Mezak; Oscar J Abilez; Evangeline Tzatzalos; Joseph C Wu; Ngan F Huang
Journal:  Biomater Sci       Date:  2017-07-25       Impact factor: 6.843

5.  Epigenetic regulation of the electrophysiological phenotype of human embryonic stem cell-derived ventricular cardiomyocytes: insights for driven maturation and hypertrophic growth.

Authors:  Maggie Zi Ying Chow; Lin Geng; Chi-Wing Kong; Wendy Keung; Jacky Chun-Kit Fung; Kenneth R Boheler; Ronald A Li
Journal:  Stem Cells Dev       Date:  2013-06-14       Impact factor: 3.272

6.  Advancing functional engineered cardiac tissues toward a preclinical model of human myocardium.

Authors:  Irene C Turnbull; Ioannis Karakikes; Gregory W Serrao; Peter Backeris; Jia-Jye Lee; Chaoqin Xie; Grant Senyei; Ronald E Gordon; Ronald A Li; Fadi G Akar; Roger J Hajjar; Jean-Sébastien Hulot; Kevin D Costa
Journal:  FASEB J       Date:  2013-10-30       Impact factor: 5.191

7.  Genetic engineering of somatic cells to study and improve cardiac function.

Authors:  Robert D Kirkton; Nenad Bursac
Journal:  Europace       Date:  2012-11       Impact factor: 5.214

Review 8.  Calcium signalling of human pluripotent stem cell-derived cardiomyocytes.

Authors:  Sen Li; Gaopeng Chen; Ronald A Li
Journal:  J Physiol       Date:  2013-09-09       Impact factor: 5.182

9.  A simple, cost-effective but highly efficient system for deriving ventricular cardiomyocytes from human pluripotent stem cells.

Authors:  Zhihui Weng; Chi-Wing Kong; Lihuan Ren; Ioannis Karakikes; Lin Geng; Jiaozi He; Maggie Zi Ying Chow; Chong Fai Mok; Wendy Keung; Howard Chow; Anskar Y H Leung; Roger J Hajjar; Ronald A Li; Camie W Chan
Journal:  Stem Cells Dev       Date:  2014-04-22       Impact factor: 3.272

10.  Transverse tubular network structures in the genesis of intracellular calcium alternans and triggered activity in cardiac cells.

Authors:  Zhen Song; Michael B Liu; Zhilin Qu
Journal:  J Mol Cell Cardiol       Date:  2017-12-05       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.